ACXP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	28 594.00
Gjennomsnittsvolum	99 434.00
Markedsverdi	32.62M
EPS	$-0.380 ( 2024-03-18 )
Neste inntjeningsdato	( $-0.240 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.0140 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.75
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: 0.65 (weak)

Signal:(59.834) Neutral

Acurx Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner
SISI	0.968
GLMD	0.965
PEAR	0.963
GMBL	0.962
PPBT	0.951
LAWS	0.948
ACET	0.945
PTE	0.944
NCBS	0.944
CYTO	0.942

10 Mest negative korrelasjoner
GXII	-0.969
CLBT	-0.961
GASS	-0.958
ISEE	-0.958
RAM	-0.957
MITA	-0.957
NECB	-0.956
IVCB	-0.955
AGGR	-0.955
CSWC	-0.954

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Acurx Pharmaceuticals, Korrelasjon - Valuta/Råvare

-0.20
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.01
( neutral )

Acurx Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.